ReNeuron raises funds as it awaits review from first treatment of stem cell therapy
This article was originally published in Scrip
Executive Summary
ReNeuron has raised £10 million by means of a share placing and subscription with new and existing investors on London's AIM. The stem cell-focused company says the financing provides preclinical and clinical development funding for core therapeutic programmes for the next two years, after which it believes that out-licensing deals will be possible for these programmes.